Two novel freeze-dried pH-sensitive cyclosporine A nanoparticles: Preparation, in vitro drug release, and in vivo absorption enhancement effects

Current Nanoscience

Volumn 5, Issue 4, 2009, Pages 449-456

  Fang, Zhi Gang ^a   Pan, Ping ^a   Yang, Zhi Qiang ^a   Chen, Ya Gen ^a   Zhang, Jian Kang ^a   Wei, Miao ^a   Zhang, Xue Nong ^a   Zhang, Qiang ^b  

^a SOOCHOW UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Bioavailability; Cyclosporine A; Enhancement absorption; Freeze drying; Nanoparticle; Pharmacokinetics

Indexed keywords

ABSORPTION ENHANCEMENT; BIOAVAILABILITY; CRYOPROTECTANTS; CYCLOSPORINE A; EMULSION SOLVENTS; ENCAPSULATION EFFICIENCY; ENHANCEMENT ABSORPTION; EUDRAGIT; FREEZE-DRIED FORMULATIONS; FREEZE-DRYING; IN-VITRO; IN-VIVO; MEAN PARTICLE SIZE; ORAL DELIVERY; PERFORMANCE EVALUATION; PH SENSITIVE; PH-SENSITIVITY; POORLY SOLUBLE DRUGS; RELATIVE BIOAVAILABILITY;

ABSORPTION; BIOCHEMISTRY; CONTROLLED DRUG DELIVERY; CURING; DEWATERING; DRUG PRODUCTS; EMULSIFICATION; ENCAPSULATION; LOW TEMPERATURE DRYING; NANOPARTICLES; PARTICLE SIZE; PHARMACOKINETICS; POTENTIOMETRIC SENSORS; SUGARS;

PH EFFECTS;

CYCLOSPORIN A; EUDRAGIT; LACTOSE; NANOPARTICLE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; EMULSION; FREEZE DRYING; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

RATTUS;

EID: 70350774064     PISSN: 15734137     EISSN: None     Source Type: Journal    
DOI: 10.2174/157341309789378140     Document Type: Article

References (44)

1. Matzke, G.R.; Luke, D.R. Dialysis and renal transplant therapy. Herfindal, E.T.; Gourley, D.R.; Hart, L.L. (Eds.). In: Clinical Pharmacy and Therapeutics. Williams & Wilkins: Baltimore, 1988, pp. 229-242.
2. Cohen, D.J.; Loertscher, R.; Rubin, M.F.; Tilney, N.L.; Carpenter, C.B.; Strom, T.B. Cyclosporine A: a new immunosuppressive agent for organ transplantation. Ann. Intern. Med., 1984, 101(5), 667-682. (Pubitemid 15223313)
3. Thomson, A.W.; Neild, G.H. Cyclosporin: use outside transplantation. BMJ, 1991, 302(6767), 4-5.
4. Sajjadi, H.; Soheilian, M.; Ahmadieh, H.; Hassanein, K.; Parvin, M.; Azarmina, M.; Ehyaee, V.; Amiransari, B. Low dose cyclosporin-A therapy in Behcet's disease. J. Ocul. Pharmacol., 1994, 10(3), 553-560. (Pubitemid 24321154)
5. Richardson, C.; Emery, P. Clinical use of cyclosporin in rheumatoid arthiritis. Drugs, 1995, 50(suppl. 1), 26-36. (Pubitemid 126664674)
6. Kahan, B.D. Recommendations concerning the introduction of generic formulations of cyclosporine. Transplant. Proc., 1999, 31(3), 1675-1684. (Pubitemid 29234969)
7. Lindholm, A.; Henricsson, S.; Lind, M.; Dahlqvist, R. Intraindividual variability in the relative systemic availability of cyclosporine after oral dosing. Eur. J. Clin. Pharmacol., 1988, 34(5), 461-464. (Pubitemid 18156439)
8. Taylor, N.E.; Mark, A.E.; Vallat, P.; Brunne, R.M.; Testa, B. Van; Gunteren, W.F. Solvent dependent conformation and hydrogen bounding capacity of cyclosporin A: evidence from partition coefficient and molecular dynamics simulations. J. Med. Chem., 1993, 36(24), 3753-3764.
9. Ismailos, G.; Reppas, C.; Dressman, J.B.; Macheras, P. Unusual solubility behavior of cyclosporin A in aqueous media. J. Pharm. Pharmacol., 1991, 43(4), 287-289.
10. Wacher, V.J.; Silverman, J.A.; Zhang, Y.; Benet, L.Z. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci., 1998, 87(11), 1322-1330. (Pubitemid 28514135)
11. Kovarik, J.M.; Mueller, E.A.; van Bree, J.B.; Tetzloff, W.; Kutz, K. Reduced inter- and intraindividual variability in cyclosporin pharmacokinetics from a microemulsion formulation. J. Pharm. Sci., 1994, 83(3), 444-446. (Pubitemid 24224228)
12. Cavanak, T.; Sucker, H. Cyclosporin: Formulation of dosage forms. Prog. Allergy, 1986, 38, 65-72.
13. Gelderblom, H.; Verweij, J.; Nooter, K.; Sparreboom, A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer, 2001, 37(3), 1590-1598.
14. Luke, D.R.; Kasiske, B.L.; Matzke, G.R.; Awni, W.M.; Keane, W.F. Effect of cyclosporin on the isolated perfused rat kidney. Transplantation, 1987, 43(6), 795-799. (Pubitemid 17084251)
15. Aberturas, M.R.; Molpeceres, J.; Guzmán, M.; García, F. Development of a new cyclosporin formulation based on poly (caprolactone) microspheres. J. Microencapsul., 2002, 19(1), 61-72. (Pubitemid 34086907)
16. Ritschel, W.A. Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral. Clin. Transplant, 1996, 10(4), 364-373.
17. Venkataram, S.; Awni, W.M.; Jordan, K.; Rahman, Y.E. Pharmacokinetics of two alternative dosage forms of cyclosporin: liposomes and intralipid. J. Pharm. Sci., 1990, 79(3), 216-219.
18. Zhang, Q.; Yie, G.; Li, Y.; Yang, Q.; Nagai, T. Studies on cyclosporin A loaded stearic acid nanoparticles. Int. J. Pharm., 2000, 200(2), 153-159. (Pubitemid 30364902)
19. Chen, X.X.; Young, T.J.; Sarkari, M.; Williams, R.O. 3rd.; Johnston, K.P. Preparation of cyclosporin A nanoparticles by evaporative precipitation intoaqueous solution. Int. J. Pharm., 2002, 242(1-2), 3-14.
20. Gref, R.; Quellec, P.; Sanchez, A.; Calvo, P.; Dellacherie, E.; Alonso, M.J. Development and characterization of CyA-loaded poly (lactic acid)-poly (ethylene glycol) PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers. Eur. J. Pharm. Biopharm., 2001, 51(2), 111-118.
21. Bala, I.; Hariharan, S.; Kumar, M.N. PLGA nanoparticles in drug delivery: the state of the art. Crit. Rev. Ther. Drug Carrier Syst., 2004, 21(5), 387-422. (Pubitemid 41647578)
22. Sonaje, K.; Italia, J.L.; Sharma, G.; Bhardwaj, V.; Tikoo, K.; Kumar, M.N. Development of biodegradable nanoparticles for oral delivery of ellagic acid and evaluation of their antioxidant efficacy against cyclosporine A-induced nephrotoxicity in rats. Pharm. Res., 2007, 24(5), 899-908. (Pubitemid 46675391)
23. Wang, X.Q.; Dai, J.D.; Chen, Z.; Zhang, T.; Xia, G.M.; Nagai, T.; Zhang, Q. Bioavailability and pharmaceutics of cyclosporine A-loaded pH sensitive nanoparticles for oral administration. J. Control Release, 2004, 97(3), 421-429. (Pubitemid 38802944)
24. Lee, W.K.; Park, J.Y.; Yang, E.H.; Suh, H.; Kim, S.H.; Chung, D.S.; Choi, K.; Yang, C.W.; Park, J.S. Investigation of factors influencing the release rates of cyclosporine A-loaded micro- and nanoparticles prepared by high-pressure homogenizer. J. Control Release, 2002, 84(3), 115-123.
25. Italia, J.L.; Bhatt, D.K.; Bhardwaj, V.; Tikoo, K.; Kumar, M.N. PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J. Control. Release, 2007, 119(2), 197-206.
26. El-Shabouri, M.H. Positively charged nanoparticles for improving the oral bioavailability of cyclosporine-A. Int. J. Pharm., 2002, 249(1-2), 101-108. (Pubitemid 35333436)
27. Eerikäinen, H.; Kauppinen, E.I. Preparation of polymeric nanoparticles containing corticosteroid by a novel aerosol flow reactor method. Int. J. Pharm., 2003, 263(1-2), 69-83. (Pubitemid 37087934)
28. Hori, M.; Onishi, H.; Machida, Y. Evaluation of Eudragit-coated chitosan microparticles as an oral immune delivery system. Int. J. Pharm., 2005, 297(1-2), 223-234. (Pubitemid 40720281)
29. Cui, F.; Wang, Y.; Wang, J.; Feng, L.; Ning, K. Preparation of an enteric-soluble solid-state emulsion using oily drugs. Int. J. Pharm., 2007, 338(1-2), 152-156. (Pubitemid 46777233)
30. De Jaeghere, F.; Allémann, E.; Leroux, J.C.; Stevels, W.; Feijen, J.; Doelker, E.; Gurny, R. Formulation and lyoprotection of poly (lactic acid-co-ethylene oxide) nanoparticles: Influence on physical stability and in vitro cell uptake. Pharm. Res., 1999, 16(6), 859-866. (Pubitemid 29284197)
31. Crowe, L.M.; Reid, D.S.; Crowe, J.H. Is trehalose special for preserving dry biomaterials? Biophys. J., 1996, 71(4), 2087-2093.
32. Fang, J.Y.; Lin, H.H.; Hsu, L.R.; Tsai, Y.H. Characterization and stability of various liposome-encapsulated enoxacin formulations. Chem. Pharm. Bull., 1997, 45(9), 1504-1509.
33. Ozaki, K.; Hayashi, M. The effects of glucose oligomers (maltodextrins) on freeze-drying liposomes. Chem. Pharm. Bull, 1997, 45(1), 165-170. (Pubitemid 27065847)
34. Kawashima, Y.; Niwa, T.; Handa, T.; Takeuchi, H.; Iwamoto, T.; Itoh, K. Preparation of controlled-release microspheresof ibuprofen with acrylic polymers by a novel quasi-emulsion solvent diffusion method. J. Pharm. Sci., 1989, 78(1), 68-72. (Pubitemid 19079816)
35. Saez, A.; Guzmán, M.; Molpeceres, J.; Aberturas, M.R. Freeze-drying of polycaprolactone and poly(D,L-lactic-glycolic) nanoparticles induce minor or particle size changes affecting the oral pharmacokinetics of loaded drugs. Eur. J. Pharm. Biopharm., 2000, 50(3), 379-387. (Pubitemid 30799173)
36. Win, K.Y.; Feng, S.S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials, 2005, 26(15), 2713-2722.
37. Hillyer, J.F.; Albrecht, R.M. Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles. J. Pharm. Sci., 2001, 90(12), 1927-1936.
38. Molpeceres, J.; Guzman, M.; Aberturas, M.R.; Chacon, M.; Berges, L. Application of central composite designs to the preparation of polycaprolactone nanoparticles by solvent displacement. J. Pharm. Sci., 1996, 85(2), 206-213. (Pubitemid 26055803)
39. Auvillain, M.; Cavé, G.; Fessi, H.; Devissaguet, J.P. Lyophilisation devecteurs collodaux submicroniques. STP Pharma., 1989, 5, 738-744.
40. Chorny, M.; Fishbein, I.; Danenberg, H.D.; Golomb, G. Study of the drug release mechanism from tyrphostin AG-1295-loaded nanospheres by in situ and external sink methods. J. Control. Release, 2002, 83(3), 401-414. (Pubitemid 35223262)
41. Wang, X.Q.; Dai, J.D.; Zhang, H.; Zhang, X.; Wang, J.C.; Zhang, Q. Absorption mechanism of cyclosporine A loaded pH-sensitive nanoparticles in rats. J. Nanosci. Nanotechnol., 2008, 8(5), 2422-2431.
42. Lennernäs, H. Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans. Curr. Drug Metab., 2007, 8(7), 645-657. (Pubitemid 47578114)
43. Tarr, B.D.; Yalkowsky, S.H. Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. Pharm. Res., 1989, 6(1), 40-43.
44. McClean, S.; Prosser, E.; Meehan, E.; O'Malley, D.; Clarke, N.; Ramtoola, Z.; Brayden, D. Binding and uptake of biodegradable poly-DL-lactide micro- and nanoparticles in intestinal epithelia. Eur. J. Pharm. Sci., 1998, 6(2), 153-163.